Active Ingredient History
Dalfampridine is a potassium channel blocker, used as a research tool in characterizing subtypes of the potassium channel. Dalfampridine has also been used as a drug, to manage some of the symptoms of multiple sclerosis, and is indicated for symptomatic improvement of walking in adults with several variations of the disease. The mechanism by which dalfampridine exerts its therapeutic effect has not been fully elucidated. Dalfampridine is a broad spectrum potassium channel blocker. In animal studies, dalfampridine has been shown to increase conduction of action potentials in demyelinated axons through inhibition of potassium channels. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Ataxia (Phase 2)
Cerebral Palsy (Phase 1)
Cognition Disorders (Phase 2/Phase 3)
Fatigue (Phase 2)
Guillain-Barre Syndrome (Phase 2)
Healthy Volunteers (Phase 1)
Ischemic Stroke (Phase 3)
Motor Neuron Disease (Phase 1)
Multiple Sclerosis, Chronic Progressive (Phase 4)
Multiple Sclerosis, Relapsing-Remitting (Phase 3)
Muscle Spasticity (Phase 3)
Muscular Atrophy, Spinal (Phase 2/Phase 3)
Myelitis (Phase 2)
Myelitis, Transverse (Phase 2)
Neuromyelitis Optica (Phase 2)
Ocular Motility Disorders (Phase 2)
Optic Neuritis (Phase 2/Phase 3)
Optic Neuropathy, Ischemic (Phase 4)
Parkinson Disease (Phase 1/Phase 2)
Renal Insufficiency (Phase 1)
Sleep Apnea, Obstructive (Phase 2)
Spinal Cord Injuries (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
